

Product Data Sheet

UK-432097

 $\begin{array}{lll} \textbf{Cat. No.:} & \text{HY-107046} \\ \textbf{CAS No.:} & 380221\text{-}63\text{-}6 \\ \textbf{Molecular Formula:} & C_{40}H_{47}N_{11}O_{6} \\ \end{array}$

Molecular Weight: 777.87

Target: Adenosine Receptor

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	UK-432097 is a highly potent and selective $A_{2A}AR$ agonist with a pK _i of 8.4 for human $A_{2A}AR$. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research ^{[1][2][3]} .
IC ₅₀ & Target	pKi: 8.4 (A2AAR) ^[1]
In Vitro	UK-432097 has an EC $_{50}$ value of 0.66 nM using CHO cells expressing human WT A $_{50}$ AR $^{[1]}$. UK-432097 (0.01, 0.1, 1, 10, 100, 1000 nM; pretreated for 2 hours) significantly increases cAMP accumulation in CHO-A2A cells $^{[3]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Fei Xu, et al. Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7.

[2]. Kenneth A Jacobson, et al. Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front Cell Neurosci. 2019 Mar 28;13:124.

[3]. J Daniel Hothersall, et al. Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Mol Pharmacol. 2017 Jan;91(1):25-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA